Zachary Silbersher
Zachary Silbersher is a patent attorney located in New York City. He is a founding member of the patent law firm, Kroub Silbersher & Kolmykov PLLC as well as the patent-consultancy at Markman Advisors LLC. He can be reached at zsilbersher@kskiplaw.com.
Posts by Zachary Silbersher
District of Delaware Makes it Harder to Corner the Market on Antibody Patents in MorphoSys v. Janssen
Patents covering an antibody are often claimed by the antibody’s function (the residues where it binds to the antigen) rather than its structure (amino-acid sequence). This …
Celgene’s New Revlimid® Lawsuits Shows Shifting Tactics From Earlier Natco Case
Celgene faces a new gang of generics moving in on its blockbuster Revlimid®. Over the past year, a number of generics have filed ANDAs against Revlimid®, including …
Did the Federal Circuit doom Amgen’s Enbrel® monopoly?
In the case, Amgen v. Sanofi, the Court vacated an injunction Amgen obtained against a competing drug to its new PCSK9-inhibitor. The Court’s decision turned …
Is TC Heartland All Good News for Patent Litigation Defendants?
Joint-defense groups lower costs and increase efficiencies for all defendants in the groups. Certain prominent patent litigation boutiques and Big Law departments have skillfully made a business …
Amgen v. Regeneron: Will the permanent injunction against Regeneron’s new PCSK9-inhibitor hold up on appeal?
On January 5, 2017, the District of Delaware issued its long-awaited decision in the patent dispute pending between Amgen and Regeneron wherein the Court granted Amgen’s request for …
McRo decision expected to clarify abstract idea doctrine under Alice
A case currently pending before the Federal Circuit is anticipated to provide greater guidance into the answer to this question, namely, how district courts should determine whether …
